KalVista Pharmaceuticals
KALVApprovedKalVista Pharmaceuticals is dedicated to advancing oral small molecule medicines for rare diseases with significant unmet needs, with its primary focus on hereditary angioedema (HAE). The company achieved a major milestone with the FDA approval of EKTERLY® (sebetralstat), the first oral on-demand treatment for HAE attacks, which is now commercially launched. Beyond its commercial product, KalVista maintains an innovative pipeline including oral Factor XIIa inhibitors for prophylactic HAE treatment and is exploring applications in thrombosis and inflammation. With over 250 employees worldwide, the company combines scientific expertise with commercial execution to transform patient care.
KALV · Stock Price
Historical price data
AI Company Overview
KalVista Pharmaceuticals is dedicated to advancing oral small molecule medicines for rare diseases with significant unmet needs, with its primary focus on hereditary angioedema (HAE). The company achieved a major milestone with the FDA approval of EKTERLY® (sebetralstat), the first oral on-demand treatment for HAE attacks, which is now commercially launched. Beyond its commercial product, KalVista maintains an innovative pipeline including oral Factor XIIa inhibitors for prophylactic HAE treatment and is exploring applications in thrombosis and inflammation. With over 250 employees worldwide, the company combines scientific expertise with commercial execution to transform patient care.
Technology Platform
Oral small molecule inhibitors targeting the kallikrein-kinin system (KKS), specifically plasma kallikrein and Factor XIIa, to control inflammation and vascular leakage for diseases like HAE.
Pipeline
13| Drug | Indication | Stage | Watch |
|---|---|---|---|
| KVD900 600 mg + KVD900 300 mg | Hereditary Angioedema | Phase 3 | |
| Placebo + KVD900 600 mg + KVD900 300 mg | Hereditary Angioedema | Phase 3 | |
| KVD900 150 mg + KVD900 300 mg + KVD900 600 mg | Hereditary Angioedema | Phase 3 | |
| KVD900 600 mg + Drug: KVD900 300 mg | Hereditary Angioedema | Phase 3 | |
| KVD001 Injection | Diabetic Macular Edema | Phase 2 |
Funding History
4FDA Approved Drugs
1Opportunities
Risk Factors
Competitive Landscape
KalVista competes in the HAE market against Takeda, CSL Behring, and BioCryst. Its primary differentiation is EKTERLY® as the first and only oral on-demand therapy. Future competition in oral prophylaxis will be direct with BioCryst's Orladeyo, requiring KalVista's Factor XIIa inhibitor to demonstrate superior efficacy, safety, or convenience.